Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
Bjoern C
BC
Harder
Stefan
S
von Baltz
Frank C
FC
Schlichtenbrede
Jost B
JB
Jonas
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001251:Astigmatism / Q000503:physiopathology; D000068258:Bevacizumab; D001724:Birth Weight; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D011446:Prospective Studies; D012030:Refractive Errors / Q000503:physiopathology*; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab